159 related articles for article (PubMed ID: 9333073)
21. Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata.
Pfaller MA; Bale MJ; Buschelman B; Rhomberg P
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):75-80. PubMed ID: 7805359
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
23. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Doern GV; Brandt ME; Hajjeh RA
Antimicrob Agents Chemother; 1998 Dec; 42(12):3242-4. PubMed ID: 9835520
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading.
Uzun O; Arikan S; Kocagöz S; Sancak B; Unal S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):101-7. PubMed ID: 11035241
[TBL] [Abstract][Full Text] [Related]
26. [Fluconazole and itraconazole susceptibility testing with clinical yeast isolates and algae of the genus Prototheca by means of the Etest].
Blaschke-Hellmessen R
Mycoses; 1996; 39 Suppl 2():39-43. PubMed ID: 9198743
[TBL] [Abstract][Full Text] [Related]
27. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
[TBL] [Abstract][Full Text] [Related]
28. Anti-candidal activity of selected analgesic drugs used alone and in combination with fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole.
Król J; Nawrot U; Bartoszewicz M
J Mycol Med; 2018 Jun; 28(2):327-331. PubMed ID: 29605543
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Swinne D; Watelle M; Nolard N
Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents.
Arias A; Arévalo MP; Andreu A; Rodríguez C; Sierra A
Mycoses; 1994; 37(7-8):285-9. PubMed ID: 7739661
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity of voriconazole against Candida species.
Kauffman CA; Zarins LT
Diagn Microbiol Infect Dis; 1998 May; 31(1):297-300. PubMed ID: 9597390
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
33. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
Panizo MM; Reviákina V; Dolande M; Selgrad S
Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
[TBL] [Abstract][Full Text] [Related]
34. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.
Johnson EM; Davey KG; Szekely A; Warnock DW
J Antimicrob Chemother; 1995 Nov; 36(5):787-93. PubMed ID: 8626259
[TBL] [Abstract][Full Text] [Related]
35. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
36. [Profile of antifungal susceptibility of species of Candida isolated from hemocultures in a university hospital, Maracaibo, Venezuela].
Arcaya NM; Mesa LM; Pineda MR; Beltrán-Luengo H; Milagros Calvo B
Rev Iberoam Micol; 2006 Jun; 23(2):97-100. PubMed ID: 16854186
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole.
Mallié M; Bastide JM
Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756
[TBL] [Abstract][Full Text] [Related]
38. Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
Sojakova M; Liptajova D; Borovsky M; Subik J
Mycopathologia; 2004 Feb; 157(2):163-9. PubMed ID: 15119851
[TBL] [Abstract][Full Text] [Related]
39. In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei.
Venkateswarlu K; Denning DW; Kelly SL
J Antimicrob Chemother; 1997 Jun; 39(6):731-6. PubMed ID: 9222042
[TBL] [Abstract][Full Text] [Related]
40. Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.
Tiballi RN; Zarins LT; He X; Kauffman CA
J Clin Microbiol; 1995 Oct; 33(10):2612-5. PubMed ID: 8567892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
